Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04527887 · ClinicalTrials.gov registry record · Phase 4
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
A Phase 4 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT04527887: Clinical Trial Phase 4 study, sponsored by Tufts Medical Center.
NCT04527887 is a Phase 4 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 54 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04527887, a Phase 4 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
This prospective, single-center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of Intracanalicular dexamethasone Insert (IDI) on ameliorating the signs and symptoms of dry eye disease.
Primary Outcome
As measured by change to dendritic cell density and ocular redness
Interventions
- DRUG Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
- OTHER ProLong™ collagen plugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-09-04 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 4 |
Why NCT04527887 stopped before completion
NCT04527887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg) is the first listed.
NCT04527887 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04527887 about?
NCT04527887 is a clinical study titled "Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)". This prospective, single-center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of Intracanalicular dexamethasone Insert (IDI) on ameliorating the signs and symptoms of dry eye disease.
What is the current status of trial NCT04527887?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2020-09-04. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04527887?
The interventions under investigation include: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg) (DRUG), ProLong™ collagen plugs (OTHER).
Who is sponsoring clinical trial NCT04527887?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04527887's enrollment target sits among peer trials
54 1223rd of 2000 higher than 772 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI